ClinicalTrials.govpublic full text
Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients
myeloproliferative neoplasm (mpn), essential thrombocythemia (et), jak2 mutation, polycythemia vera (pv), primary myelofibrosis, venous thromboembolism (vte), interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 875294
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.